Capital International Investors’s Vertex Pharmaceuticals VRTX Stock Holding History

Capital International Investors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.33B	Sell	4,695,144 -430,933	-8%	-$191M	0.48%	53
2026 Q1	$2.29B	Buy	5,126,077 +392,481	+8%	+$183M	0.54%	52
2025 Q4	$2.15B	Buy	4,733,596 +44,537	+0.9%	+$19.2M	0.34%	67
2025 Q3	$1.84B	Buy	4,689,059 +2,053,156	+78%	+$858M	0.3%	79
2025 Q2	$1.17B	Buy	2,635,903 +1,986,004	+306%	+$915M	0.2%	104
2025 Q1	$315M	Buy	649,899 +307,387	+90%	+$143M	0.06%	191
2024 Q4	$138M	Buy	+342,512	New	+$159M	0.03%	257
2022 Q2	–	Sell	-125,595	Closed	-$32.8M	–	460
2022 Q1	$32.8M	Sell	125,595 -1,901,637	-94%	-$451M	0.01%	376
2021 Q4	$445M	Sell	2,027,232 -1,922,320	-49%	-$374M	0.09%	189
2021 Q3	$716M	Sell	3,949,552 -599,451	-13%	-$117M	0.16%	136
2021 Q2	$917M	Sell	4,549,003 -1,493,566	-25%	-$312M	0.21%	110
2021 Q1	$1.3B	Sell	6,042,569 -642,853	-10%	-$141M	0.33%	84
2020 Q4	$1.58B	Buy	6,685,422 +1,199,338	+22%	+$275M	0.43%	61
2020 Q3	$1.49B	Sell	5,486,084 -261,425	-5%	-$72.1M	0.46%	56
2020 Q2	$1.67B	Sell	5,747,509 -795,089	-12%	-$216M	0.55%	43
2020 Q1	$1.56B	Buy	6,542,598 +277,804	+4%	+$63.7M	0.64%	40
2019 Q4	$1.37B	Buy	6,264,794 +3,241,404	+107%	+$656M	0.47%	58
2019 Q3	$512M	Buy	3,023,390 +123	+0%	+$21.8K	0.2%	121
2019 Q2	$554M	Sell	3,023,267 -66,904	-2%	-$11.7M	0.22%	110
2019 Q1	$568M	Buy	3,090,171 +392,648	+15%	+$72.5M	0.24%	109
2018 Q4	$447M	Sell	2,697,523 -174,400	-6%	-$30.2M	0.22%	114
2018 Q3	$554M	Buy	+2,871,923	New	+$511M	0.25%	100
2015 Q3	–	Sell	-111	Closed	-$14K	–	271
2015 Q2	$14K	Buy	+111	New	+$14K	﹤0.01%	257

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Capital International Investors's VRTX Position: Q2 2026 in Review

Capital International Investors reduced its Vertex Pharmaceuticals (VRTX) stake by 8.4% in Q2 2026, selling an estimated $191M and leaving 4,695,144 shares worth $2.33B. The position accounts for 0.48% of the portfolio, ranked #53.

Capital International Investors first reported a position in VRTX in Q2 2015 and has held it in 23 quarters since. 1,762 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Capital International Investors held 4,695,144 shares of Vertex Pharmaceuticals worth $2.33B as of Q2 2026.
Capital International Investors sold 430,933 Vertex Pharmaceuticals shares in Q2 2026, an estimated $191M.
Vertex Pharmaceuticals made up 0.48% of Capital International Investors's portfolio in Q2 2026, its #53 holding.
Capital International Investors first reported a position in Vertex Pharmaceuticals in Q2 2015 and has held it in 23 quarters since.
1,762 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Capital International Investors's 13F filing for Q2 2026, filed 12 Aug 2026.